JP2022538898A5 - - Google Patents
Info
- Publication number
- JP2022538898A5 JP2022538898A5 JP2021578078A JP2021578078A JP2022538898A5 JP 2022538898 A5 JP2022538898 A5 JP 2022538898A5 JP 2021578078 A JP2021578078 A JP 2021578078A JP 2021578078 A JP2021578078 A JP 2021578078A JP 2022538898 A5 JP2022538898 A5 JP 2022538898A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- less
- dosage
- oatp
- reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869389P | 2019-07-01 | 2019-07-01 | |
| US62/869,389 | 2019-07-01 | ||
| PCT/US2020/040515 WO2021003279A1 (en) | 2019-07-01 | 2020-07-01 | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538898A JP2022538898A (ja) | 2022-09-06 |
| JP2022538898A5 true JP2022538898A5 (cg-RX-API-DMAC7.html) | 2023-07-11 |
| JP7704690B2 JP7704690B2 (ja) | 2025-07-08 |
Family
ID=71895194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578078A Active JP7704690B2 (ja) | 2019-07-01 | 2020-07-01 | 抗癌化合物e7766の治療コンプライアンスを向上させるシステム |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564600B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3993809B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7704690B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220029717A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114599374A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020300543A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026876A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3145824A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000052A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021003279A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4398901A1 (en) | 2021-09-09 | 2024-07-17 | Eisai R&D Management Co., Ltd. | Biomarkers for sting agonists and methods of using the same |
| CN115512788B (zh) * | 2022-09-16 | 2023-08-08 | 山东大学 | 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2446893A1 (en) | 2010-11-01 | 2012-05-02 | Bergen Teknologioverføring AS | Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters |
| WO2013169616A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmacokinetic modulation with alisporivir |
| BR112017018861A2 (pt) | 2015-03-04 | 2018-04-24 | Board Of Regents, The Unibersity Of Texas System | métodos para tratar câncer mantendo perda hemizigótica de tp53 |
| MX2018010850A (es) | 2016-03-10 | 2019-05-15 | Univ Johns Hopkins | Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos. |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| WO2019004466A1 (ja) | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬 |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
-
2020
- 2020-07-01 BR BR112021026876A patent/BR112021026876A2/pt unknown
- 2020-07-01 JP JP2021578078A patent/JP7704690B2/ja active Active
- 2020-07-01 US US17/597,199 patent/US12564600B2/en active Active
- 2020-07-01 KR KR1020227003441A patent/KR20220029717A/ko active Pending
- 2020-07-01 AU AU2020300543A patent/AU2020300543A1/en active Pending
- 2020-07-01 MX MX2022000052A patent/MX2022000052A/es unknown
- 2020-07-01 CA CA3145824A patent/CA3145824A1/en active Pending
- 2020-07-01 EP EP20750022.4A patent/EP3993809B1/en active Active
- 2020-07-01 WO PCT/US2020/040515 patent/WO2021003279A1/en not_active Ceased
- 2020-07-01 CN CN202080061033.0A patent/CN114599374A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McLaughlin et al. | Dolutegravir-induced hyperglycaemia in a patient living with HIV | |
| Fazil et al. | Bisphosphonates: therapeutics potential and recent advances in drug delivery | |
| EP4322942B1 (en) | Combination comprising everolimus and amcenestrant | |
| TWI533866B (zh) | 卡巴利他索(cabazitaxel)之新穎抗腫瘤用途 | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| US20180117042A1 (en) | Methods for treating respiratory syncytial virus infection | |
| CN105579018A (zh) | 预制备用于治疗用途的药物的方法 | |
| WO2019051387A1 (en) | METHODS OF USING DIPIVECHINE | |
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2023537921A5 (cg-RX-API-DMAC7.html) | ||
| CN103327975A (zh) | 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物 | |
| JP2023548429A5 (cg-RX-API-DMAC7.html) | ||
| US20170209458A9 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| JP2025517509A5 (cg-RX-API-DMAC7.html) | ||
| KR20200021945A (ko) | 의약 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
| IL173847A (en) | Pharmaceutical composition in a form of anhydrous self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs | |
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| Sims-McCallum | Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. | |
| RU2022101963A (ru) | Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766 |